Patents by Inventor Hyun Uk Kim
Hyun Uk Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180344866Abstract: A liquid formulation of highly concentrated long-acting human growth hormone conjugate contains a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent. A method for preparing the same is provided.Type: ApplicationFiled: July 25, 2018Publication date: December 6, 2018Applicant: HANMI SCIENCE CO., LTD.Inventors: Hyung Kyu LIM, Hyun Uk KIM, Sung Hee HONG, Sung Min BAE, Se Chang KWON
-
Publication number: 20180256731Abstract: An insulin analog has a reduced insulin titer and a reduced insulin receptor binding affinity compared to the native form for the purpose of increasing the blood half-life of insulin. A conjugate is prepared by linking the insulin analog and a carrier. A long-acting formulation includes the conjugate.Type: ApplicationFiled: May 18, 2018Publication date: September 13, 2018Applicant: HANMI PHARM. CO., LTDInventors: Sang Youn Hwang, Yong Ho Huh, Jin Young Kim, Sung Hee Hong, In Young Choi, Sung Youb Jung, Se Chang Kwon, Dae Jin Kim, Hyun Uk Kim, Myung Hyun Jang, Seung Su Kim
-
Patent number: 10064951Abstract: The present invention relates to a liquid formulation of highly concentrated long-acting human growth hormone conjugate, comprising a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent, and a method for preparing the same.Type: GrantFiled: March 23, 2013Date of Patent: September 4, 2018Assignee: HANMI SCIENCE CO., LTD.Inventors: Hyung Kyu Lim, Hyun Uk Kim, Sung Hee Hong, Sung Min Bae, Se Chang Kwon
-
Patent number: 10046061Abstract: Provided are an insulin conjugate having improved insulin receptor binding affinity and increased activity, in which a non-peptidyl polymer and an immunoglobulin Fc region are site-specifically linked to an amino acid residue of the insulin beta chain excluding the N-terminus thereof via a covalent bond, a long-acting formulation including the same, and a preparation method thereof. The insulin conjugate of the present invention is used to provide an insulin formulation which exhibits a remarkably increased in vivo activity of the peptide.Type: GrantFiled: February 26, 2014Date of Patent: August 14, 2018Assignee: HANMI PHARM. CO., LTDInventors: Myung Hyun Jang, Dae Jin Kim, Sang Youn Hwang, Hyun Uk Kim, Sung Youb Jung, Se Chang Kwon
-
Publication number: 20180135895Abstract: Disclosed are an adsorption type cooling apparatus using nanoporous aluminophosphate as a water vapor adsorbent, and an operation method thereof. Specifically, the adsorption type cooling apparatus uses nanoporous aluminophosphate exhibiting a high dynamic water vapor adsorption capacity as a water vapor adsorbent. The adsorption type cooling apparatus includes at least two adsorption towers containing a water vapor adsorbent, a condenser alternately connected to the adsorption towers, and an evaporator alternately connected to the adsorption towers, wherein the water vapor adsorbent is nanoporous aluminophosphate containing aluminum, phosphorous, and oxygen.Type: ApplicationFiled: July 20, 2017Publication date: May 17, 2018Inventors: Kanghee CHO, Jong-Nam Kim, Hee Tae Beum, Sang Kyum Kim, Eunkyung Lee, Hyun-uk Kim, Sang-Sup Han, Hyung Chul Yoon, Dong-Woo Cho
-
Publication number: 20180015175Abstract: Provided are a liquid formulation of long-acting insulinotropic peptide conjugate, containing a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.Type: ApplicationFiled: September 25, 2017Publication date: January 18, 2018Applicant: HANMI PHARM. CO., LTD.Inventors: Hyun Uk KIM, Hyung Kyu LIM, Sung Hee HONG, Dae Jin KIM, Sung Min BAE, Se Chang KWON
-
Publication number: 20170360939Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.Type: ApplicationFiled: June 29, 2017Publication date: December 21, 2017Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
-
Patent number: 9833516Abstract: The present invention relates to a liquid formulation of a combination of long-acting insulin and insulinotropic peptide, comprising insulin which is a physiologically active peptide, insulinotropic peptide, and albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent; and a method for preparing the liquid formulation. The liquid formulation of the present invention does not contain a human serum albumin and potentially toxic factors to the body, and thus it has excellent storage stability for insulin conjugate and insulinotropic peptide conjugate at high concentration, without a risk of viral contamination.Type: GrantFiled: July 25, 2013Date of Patent: December 5, 2017Assignee: HANMI PHARM. CO., LTDInventors: Hyung Kyu Lim, Hyun Uk Kim, Mi Kyoung Lee, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
-
Patent number: 9801950Abstract: The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.Type: GrantFiled: July 25, 2013Date of Patent: October 31, 2017Assignee: HANMI PHARM. CO., LTD.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Sung Hee Hong, Dae Jin Kim, Sung Min Bae, Se Chang Kwon
-
Patent number: 9724420Abstract: Disclosed are an albumin-free liquid formulation including a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, and a method for preparing the liquid formulation. The liquid formulation contains a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection. The oxyntomodulin conjugate contains oxyntomodulin linked to an immunoglobulin Fc region, and thus has a large molecular weight, prolonged physiological activity, and excellent storage stability, compared to native oxyntomodulin.Type: GrantFiled: November 6, 2013Date of Patent: August 8, 2017Assignee: Hanmi Pharm. Co., Ltd.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
-
Publication number: 20170101455Abstract: The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.Type: ApplicationFiled: January 20, 2015Publication date: April 13, 2017Applicant: HANMI PHARM. CO., LTD.Inventors: Sung Youb JUNG, Sang Youn HWANG, Euh Lim OH, Sung Hee PARK, Hyun Uk KIM, Chang Ki LIM, Se Chang KWON
-
Patent number: 9566567Abstract: A metal-carbon composite supported catalyst for hydrogen production using co-evaporation and a method of preparing the same, wherein the catalyst is configured such that a metal-carbon composite having a core-shell structure resulting from co-evaporation is supported on the surface of an oxide-based support coated with carbon, thereby maintaining superior durability without agglomeration even in a catalytic reaction at a high temperature. Because part or all of the surface of metal is covered with the carbon shell, even when the catalyst is applied under severe reaction conditions including high temperatures, long periods of time, acidic or alkaline states, etc., the metal particles do not agglomerate or are not detached, and do not corrode, thus exhibiting high performance and high durability. Therefore, inactivation of the catalyst or the generation of side reactions can be prevented, so that the catalyst can be efficiently utilized in hydrogen production.Type: GrantFiled: September 18, 2013Date of Patent: February 14, 2017Assignee: KOREA INSTITUTE OF ENERGY RESEARCHInventors: Hee Yeon Kim, Seok Yong Hong, Hyun Uk Kim
-
Publication number: 20170008766Abstract: Provided is a method of synthesizing boron nitride, comprising the steps of: preparing a boron compound and a nitrogen compound; mixing the boron compound and the nitrogen compound in a non-aqueous solvent; forming an ester compound by melting the mixture in the non-aqueous solvent; dehydrating the ester compound; and forming boron nitride by nitriding the ester compound in a reductive atmosphere.Type: ApplicationFiled: July 7, 2016Publication date: January 12, 2017Applicant: KOREA INSTITUTE OF ENERGY RESEARCHInventors: In Sub HAN, Se Young KIM, Hyun Uk KIM, Young Hoon SEONG, Sang Kuk WOO, Hee Yeon KIM, Doo Won SEO, Min Soo SUH, Seong OK HAN
-
Publication number: 20160213789Abstract: The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.Type: ApplicationFiled: September 26, 2014Publication date: July 28, 2016Applicant: HANMI PHARM. CO., LTD.Inventors: Hwa Peoung RIM, Hyun Uk KIM, Ho Taek IM, Sang Yun KIM, Hyung Kyu LIM, Sung Min BAE, Se Chang KWON
-
Publication number: 20160215278Abstract: A method for mass production of human coagulation factor VII derivatives. The method employs an expression vector, containing i) a nucleotide sequence of DHFR promoter devoid of at least one CCGCCC repeat sequence from the GC-rich region thereof and a nucleotide sequence encoding a DHFR operably linked thereto, and ii) a nucleotide sequence of CMV early gene promoter and a nucleotide sequence encoding a human coagulation factor VII derivative operably linked thereto; and adds at least one selected from the group consisting of sodium butyrate, vitamin K, and a culture medium supplement.Type: ApplicationFiled: August 27, 2014Publication date: July 28, 2016Applicant: HANMI PHARM. CO., LTD.Inventors: Hee Chul KANG, Jin Young KIM, Byung Sun LEE, Hyun Uk KIM, In Young CHOI, Se Chang KWON
-
Publication number: 20160008483Abstract: The present invention relates to an insulin analog that has a reduced insulin titer and a reduced insulin receptor binding affinity compared to the native form for the purpose of increasing the blood half-life of insulin, a conjugate prepared by linking the insulin analog and a carrier, a long-acting formulation including the conjugate, and a method for preparing the conjugate.Type: ApplicationFiled: February 26, 2014Publication date: January 14, 2016Applicant: HANMI PHARM. CO., LTDInventors: Sang Youn HWANG, Yong Ho HUH, Jin Young KIM, Sung Hee HONG, In Young CHOI, Sung Youb JUNG, Se Chang KWON, Dae Jin KIM, Hyun Uk KIM, Myung Hyun JANG, Seung Su KIM
-
Publication number: 20160000931Abstract: Provided are an insulin conjugate having improved insulin receptor binding affinity and increased activity, in which a non-peptidyl polymer and an immunoglobulin Fc region are site-specifically linked to an amino acid residue of the insulin beta chain excluding the N-terminus thereof via a covalent bond, a long-acting formulation including the same, and a preparation method thereof. The insulin conjugate of the present invention is used to provide an insulin formulation which exhibits a remarkably increased in vivo activity of the peptide.Type: ApplicationFiled: February 26, 2014Publication date: January 7, 2016Applicant: HANMI PHARM. CO., LTD.Inventors: Myung Hyun JANG, Dae Jin KIM, Sang Youn HWANG, Hyun Uk KIM, Sung Youb JUNG, Se Chang KWON
-
Publication number: 20150290324Abstract: Disclosed are an albumin-free liquid formulation including a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, and a method for preparing the liquid formulation. The liquid formulation contains a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection. The oxyntomodulin conjugate contains oxyntomodulin linked to an immunoglobulin Fc region, and thus has a large molecular weight, prolonged physiological activity, and excellent storage stability, compared to native oxyntomodulin.Type: ApplicationFiled: November 6, 2013Publication date: October 15, 2015Applicant: HANMI PHARM. CO., LTD.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
-
Publication number: 20150238629Abstract: The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.Type: ApplicationFiled: July 25, 2013Publication date: August 27, 2015Applicant: HANMI PHARM. CO., LTD.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Sung Hee Hong, Dae Jin Kim, Sung Min Bae, Se Chang Kwon
-
Publication number: 20150196643Abstract: The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection.Type: ApplicationFiled: July 25, 2013Publication date: July 16, 2015Applicant: HANMI PHARM. CO., LTD.Inventors: Hyung Kyu Lim, Hyun Uk Kim, Sung Hee Hong, Min Young Kim, Sung Min Bae, Se Chang Kwon